Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis

Vaccine

Volumn 16, Issue 20, 1998, Pages 1907-1916

  Storsaeter, Jann ^a,c   Hallander, Hans O ^b   Gustafsson, Lennart ^b   Olin, Patrick ^b  

^a SACHS CHILDREN S HOSPITAL   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c Box 4092   (Sweden)

Author keywords

Antibodies; Pertussis; Vaccine efficacy

Indexed keywords

BACTERIAL ANTIGEN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; FORMALDEHYDE; GLUTARALDEHYDE; HEMAGGLUTININ; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BORDETELLA PERTUSSIS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPOSURE; FIMBRIA; HUMAN; INFECTION PREVENTION; INTRAMUSCULAR DRUG ADMINISTRATION; PERTUSSIS; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; REGRESSION ANALYSIS; TREATMENT OUTCOME; VACCINATION;

ADHESINS, BACTERIAL; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; BIOLOGICAL MARKERS; BORDETELLA PERTUSSIS; COMMUNITY-ACQUIRED INFECTIONS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIMBRIAE PROTEINS; FIMBRIAE, BACTERIAL; HEMAGGLUTININS; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; NASAL LAVAGE FLUID; NASOPHARYNX; PERTUSSIS TOXIN; PERTUSSIS VACCINE; TREATMENT OUTCOME; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 0032374254     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00227-8     Document Type: Article

References (45)

1. 1 Corbel, M.J. and Xing, D.K.L. A consideration of control requirements for acellular pertussis vaccines. Dev. Biol. Stand. 1997, 89, 343-347.
2. 2 Gustafsson, L., Hallander, H.O., Olin, P., Reizenstein, E. and Storsaeter, J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 1996, 334, 349-355.
3. 3 Olin, P., Rasmussen, F., Gustafsson, L., Hallander, H.O. and Heijbel, H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 1997, 350, 1569-1577.
4. 4 Mooi, F.R., van Oirschot, H., Heuvelman, K., van der Heide, H., Gaastra, W. and Willems, R.J.L. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in the Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect. Immun. 1998, 66, 670-675.
5. 5 Hewlett, E.L. Pertussis: current concepts of pathogenesis and prevention. Pediatr. Infect. Dis. J. 1997, 16, S78-S84.
6. 6 Ryan, M., Murphy, G., Gothefors, L., Nilsson, L., Storsaeter, J. and Mills, K.H.G. Bordetella pertussis respiratory infection in children is associated with preferential activation of Type 1 T helper cells. J. Infect. Dis. 1997, 175, 1246-1250.
7. 7 Mills, K.H.G., Ryan, M., Ryan, E. and Mahon, B.P. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 1998, 66, 594-602.
8. 8 Siber, G.R. Methods for estimating serological correlates of protection. Dev. Biol. Stand. 1997, 89, 283-296.
9. 9 Edwards, K.M., Meade, B.D. and Decker, M.D. et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995, 96, S548-S557.
10. 10 Plotkin, S.A. and Cadoz, M. The acellular pertussis vaccine trials: an interpretation. Pediatr. Infect. Dis. J. 1997, 16, 508-517.
11. 11 Olin, P. Commentary: the best acellular pertussis vaccines are multicomponent. Pediatr. Infect. Dis. J. 1997, 16, 517-519.
12. 12 Robbins, J.B., Pittman, M., Trollfors, B., Lagergård, T.A. and Taranger, J. Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine. Pediatr. Infect. Dis. J. 1993, 12, 795-807.
13. 13 Leininger, E., Bowen, S. and Renauld-Mongénie, G. et al. Immunodominant domains present on the Bordetella pertussis vaccine component filamentous hemagglutinin. J. Infect. Dis. 1997, 175, 1423-1431.
14. 14 Shahin, R.D., Brennan, M.J., Li, Z.M., Meade, B.D. and Manclark, C.R. Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J. Exp. Med. 1990, 171, 63-73.
15. 15 Geuijen, C.A.W., Willems, R.J.L. and Mooi, F.R. The major fimbrial subunit of Bordetella pertussis binds to sulfated sugars. Infect. Immun. 1996, 64, 2657-2665.
16. 16 Gustafsson, L., Hallander, H.O., Olin, P., Reizenstein, E. and Storsaeter, J. Pertussis vaccine Trial I: technical report with preplanned analyses of safety, efficacy and immunogenicity. SMI-tryck 105. Swedish Institute for Infectious Disease Control, Stockholm, 1995.
17. 17 Hallander, H.O. Diagnostic pertussis serology in the recent clinical efficacy studies of acellular vaccines. Dev. Biol. Stand. 1997, 89, 205-212.
18. 18 Lynn, F., Reed, G.F. and Meade, B.D. Collaborative study for the evaluation of enzyme-linked immunosorbent assays used to measure human antibodies to Bordetella pertussis antigens: quantitative agreement. Clinical and Diagnostic Laboratory Immunology 1996, 3, 689-700.
19. 19 Meade, B.D., Deforest, A. and Edwards, K.M. et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics 1995, 96, S570-S575.
20. 20 Reizenstein, E., Hallander, H.O., Blackwelder, W.C., Kühn, I., Ljungman, M. and Möllby, R. Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. J. Immunol. Methods 1995, 183, 279-290.
21. 21 Hallander, H.O. and Reizenstein, E. Immunogenicity of acellular pertussis vaccines. Biologicals 1994, 22, 391-395.
22. 22 Katz, D., Baptista, J., Azen, S.P. and Pike, M.C. Obtaining confidence intervals for the risk ratio in cohort studies. Biometrics 1978, 34, 469-474.
23. 23 WHO meeting on case definition of pertussis, Geneva, 10-11 January 1991. MIM/EPI/PERT/91.1, 1-8.
24. 24 Hosmer, D.W. and Lemeshow, S. Applied Logistic Regression. John Wiley and Sons, New York, 1989
25. 25 Tiru, M., Askelöf, P., Granström, M. and Hallander, H.O. Bordetella pertussis serotype of clinical isolates in Sweden during 1970-1995 and influence of vaccine efficacy studies. Dev. Biol. Stand. 1997, 89, 239-245.
26. 26 Giuliano, M., Mastrantonio, P. and Giammanco, A. et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Dev. Biol. Stand. 1997, 89, 275-278.
27. 27 Ramsay, M.E.B., Corbel, M.J., Redhead, K., Ashworth, L.A.E. and Begg, N.T. Persistence of antibody after accelerated immunisation with diphtheria/tetanus/pertussis vaccine. Br. Med. J. 1991, 302, 1489-1491.
28. 28 Storsaeter, J., Blackwelder, W.C. and Hallander, H.O. Pertussis antibodies, protection, and vaccine efficacy after household exposure. Am. J. Dis. Child. 1992, 146, 167-172.
29. 29 Fine, P.E.M., Clarkson, J.A. and Miller, E. The efficacy of pertussis vaccines under conditions of household exposure. Int. J. Epidemiol. 1988, 17, 635-642.
30. 30 Blackwelder, W.C., VanRaden, M.J. and Deloria, M.A. Estimation of pertussis vaccine efficacy in the presence of covariates in three randomized trials. Dev. Biol. Stand. 1997, 89, 161-166.
31. 31 Simondon, F., Preziosi, M.-P. and Yam, A. et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997, 15, 1606-1612.
32. 32 Liese, J.G., Meschievitz, C.K. and Harzer, E. et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr. Infect. Dis. J. 1997, 16, 1038-1044.
33. 33 Storsaeter, J. and Gustafsson, L. Absolute efficacy of acellular pertussis vaccines in household settings. Dev. Biol. Stand. 1997, 89, 153-159.
34. 34 Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. Lancet 1988, 1, 955-960.
35. 35 Heininger, U, Cherry, J.D. and Stehr, K et al. Comparative efficacy of the Lederle/Takeda acellular pertussis component DTP (DtaP) vaccine and Lederle whole-cell component DTP vaccine in German children following household exposure (in press).
36. 36 Deen, J.L., Mink, C.A.M. and Cherry, J.D. et al. Household contact study of Bordetella pertussis infections. Clin. Infect. Dis. 1995, 21, 1211-1219.
37. 37 Mink, C.M., O'Brien, C.H., Wassilak, S., Deforest, A. and Meade, B.D. Isotype and antigen specificity of pertussis agglutinins following whole-cell pertussis vaccination and infection with Bordetelta pertussis. Infect. Immun. 1994, 62, 1118-1120.
38. 38 Sako, W. Studies on pertussis immunization. J. Pediatr. 1947, 30, 29-40.
39. 39 Miller, J.J. Jr., Silverberg, R.J., Saito, T.M. and Humber, J.B. An agglutinative reaction for Hemophilus pertussis. II. Its relation to clinical immunity. J. Pediatr. 1943, 22, 644-651.
40. 40 Medical Research Council. Vaccination against whooping cough: relation between protection in children and results of laboratory tests. Br. Med. J. 1956, 2, 454-462.
41. 41 Ramkisson, A., Coovadia, H.M. and Loening, W.E.K. Subclinical pertussis in incompletely vaccinated and unvaccinated infants. S. Afr. Med. J. 1995, 85, 662-667.
42. 42 Cherry, J.D., Gornbein J., Heininger, U. and Stehr, K. A search for serologic correlates of immunity to Bordetella pertussis infection. Vaccine 1998, 16, 1901-1906.
43. 43 Mills, K.H.G., Barnard, A., Watkins, J. and Redhead, K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect. Immun. 1993, 61, 399-410.
44. 44 Storsaeter, J. and Olin, P. Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance. Vaccine 1992, 10, 142-144.
45. 45 He, Q., Viljanen, M.K. and Ölander, R.-M. et al. Antibodies to filamenteous hemagglutinin of Bordetella pertussis and protection of whooping cough in school children. J. Infect. Dis. 1994, 170, 705-708.